Young Sailor’s Battle With HPV Sparks Global Prevention Campaign
At just 25 years old, professional sailor Eliaz Morineau has already faced a health challenge that most young men never anticipate: the removal of precancerous lesions caused by human papillomavirus (HPV). Now, as he competes in one of France’s most prestigious sailing events, Morineau is using his platform to raise awareness about a virus that affects millions worldwide—yet remains shrouded in stigma and misinformation.
Morineau’s story gained public attention during the 2026 edition of the Banque Populaire Grand Ouest (BPGO) Trophy, a high-profile sailing race that departs from and returns to Concarneau, Brittany. On April 25, 2026, he welcomed two key figures in France’s public health landscape aboard his boat, *Figaro 3 “Demain sans HPV”* (“Tomorrow Without HPV”): Caroline Semaille, Director of Santé publique France, and Laure Roulle, founder of the patient advocacy group No Taboo and spokesperson for the collective *Demain sans HPV*. Their presence underscored a growing movement to combat HPV-related diseases, which the World Health Organization (WHO) estimates cause 5% of all cancers globally.
For Morineau, the issue is deeply personal. “It’s a personal commitment to talk about HPV,” he said during the event. “I’ve been confronted with pathologies caused by this virus.” While he has not disclosed the specific type of HPV-related condition he faced, his experience aligns with a broader public health challenge: HPV is not just a “women’s issue.” Men, too, are at risk for cancers of the throat, anus, and penis, as well as genital warts. Yet vaccination rates among boys and young men lag behind those of girls in many countries, including France.
The Silent Epidemic: HPV’s Global Impact
Human papillomavirus is the most common sexually transmitted infection worldwide, with nearly all sexually active people contracting at least one type of HPV at some point in their lives. While most infections clear on their own, persistent infections with high-risk HPV types can lead to cancer. According to the WHO, HPV is responsible for:
- 99% of cervical cancers
- 90% of anal cancers
- 70% of oropharyngeal cancers (throat, tongue, tonsils)
- 60% of penile cancers
- 70% of vaginal and vulvar cancers
Despite these staggering figures, HPV remains poorly understood by the general public. A 2023 study published in *The Lancet Global Health* found that only 30% of adults in high-income countries could correctly identify HPV as a cause of cancer in men. This knowledge gap is particularly pronounced among young men, who are less likely to be vaccinated or screened for HPV-related diseases.
From Engineering to Sailing: Morineau’s Unconventional Advocacy
Morineau’s journey to becoming an HPV awareness advocate is as unconventional as his career path. Born and raised in Brittany, he developed a passion for sailing at a young age, inspired by the Vendée Globe, the grueling solo round-the-world race. After earning a degree in naval engineering, he spent four years working with MerConcept, the elite sailing team founded by François Gabart, a legend in French offshore racing.
In 2024, Morineau made the leap to professional sailing, leaving his engineering job to pursue his dream. But his ambitions extended beyond competition. “At sea, you’re alone, vulnerable,” he reflected. “But that immense freedom can also serve as a megaphone.” Initially drawn to environmental causes, his focus shifted dramatically in late 2024 when he discovered he was carrying HPV. “I had never been informed or vaccinated,” he said. “And yet, this virus can cause cancers in women—and in men, too.”
His experience mirrors a broader trend: HPV vaccination rates among boys in France have historically lagged behind those of girls. While France introduced HPV vaccination for girls in 2007, it was only in 2021 that the Haute Autorité de Santé (HAS) recommended extending the vaccine to boys aged 11–14, with a catch-up program for those up to 19. Even now, vaccination coverage remains uneven. Data from Santé publique France shows that only 41% of 15-year-old boys had received at least one dose of the HPV vaccine by 2022, compared to 53% of girls the same age.
A Boat as a Beacon: The “Demain sans HPV” Initiative
Morineau’s advocacy took tangible form in 2025 when he partnered with the association *No Taboo*, a member of the *Demain sans HPV* collective. Together, they launched a bold project: a racing boat emblazoned with the campaign’s name, *Figaro 3 “Demain sans HPV”*, designed to spark conversations about HPV prevention. The boat made its debut during the 2026 BPGO Trophy, where Morineau and his crew sailed alongside public health officials and patient advocates.
The initiative is part of a larger push to normalize discussions about HPV. “There’s still a lot of taboo around this virus,” said Laure Roulle, whose organization supports cancer patients and survivors. “Many people don’t realize that HPV doesn’t discriminate—it affects everyone, regardless of gender or sexual orientation.” Roulle’s own work focuses on breaking down the stigma associated with HPV-related cancers, which can carry a heavy emotional burden for patients.
Caroline Semaille, Director of Santé publique France, emphasized the importance of such grassroots efforts. “Public health campaigns require trusted messengers,” she noted during the BPGO event. “Eliaz’s story resonates with young people, and his platform gives us a unique opportunity to reach audiences that traditional campaigns might miss.”
The Science Behind HPV: Why Prevention Matters
HPV is a group of more than 200 related viruses, with over 40 types transmitted through sexual contact. While most infections are asymptomatic and resolve on their own, persistent infections with high-risk types (such as HPV-16 and HPV-18) can lead to cancer. The virus is so common that the U.S. Centers for Disease Control and Prevention (CDC) estimates that nearly 80 million Americans—about one in four—are currently infected with HPV.
Prevention is multifaceted. The HPV vaccine, first introduced in 2006, is highly effective at preventing infections with the most dangerous HPV types. The latest version of the vaccine, Gardasil 9, protects against nine HPV types, including those responsible for 90% of cervical cancers and a significant proportion of other HPV-related cancers. The WHO recommends vaccination for girls and boys aged 9–14, with catch-up programs for older adolescents and young adults.
Although, vaccination is only one part of the equation. Regular screening, such as Pap tests for cervical cancer, remains critical for early detection. For men, Notice no routine HPV screening tests, making vaccination and awareness even more vital. Research published in *The Journal of Infectious Diseases* in 2023 found that vaccinating boys could prevent up to 30% of HPV-related cancers in men, in addition to reducing transmission to their partners.
Global Disparities in HPV Prevention
While countries like Australia and the United Kingdom have made significant strides in HPV vaccination—Australia is on track to eliminate cervical cancer by 2035—other nations lag behind. In France, vaccination rates remain below the 80% target set by the government. Barriers include misinformation, vaccine hesitancy, and a lack of awareness about HPV’s impact on men.
Morineau’s story highlights another critical issue: the gender gap in HPV awareness. “When I was diagnosed, I realized how little I knew about HPV,” he said. “Most of the information out there is targeted at women, but men need to be part of this conversation, too.” His advocacy is part of a growing movement to reframe HPV as a universal health issue, not just a women’s health concern.
What’s Next for HPV Prevention?
The fight against HPV is entering a recent phase, with innovations in treatment and prevention on the horizon. Researchers are exploring several promising avenues, including:
- Therapeutic vaccines: Unlike prophylactic vaccines, which prevent infection, therapeutic vaccines aim to treat existing HPV-related diseases by stimulating the immune system to attack infected cells. Several candidates are in clinical trials, including one developed by the U.S. National Institutes of Health (NIH).
- Antiviral therapies: Currently, there are no drugs that directly target HPV. However, researchers are investigating substances that block the virus’s entry into cells or inhibit its replication. A 2024 review in *International Journal of Molecular Sciences* highlighted several plant-derived compounds with potential antiviral properties against HPV.
- Expanded vaccination programs: Some countries are considering lowering the age of vaccination to as young as 9, while others are exploring school-based programs to improve coverage. In France, Santé publique France has launched a new campaign to boost vaccination rates among boys, with a target of 60% coverage by 2027.
For Morineau, the next steps are clear. “I want to preserve sailing, keep racing, and keep talking about HPV,” he said. “This virus doesn’t care if you’re a man or a woman, young or old. We all have a role to play in prevention.” His boat, *Figaro 3 “Demain sans HPV”*, will continue to serve as a floating billboard for the cause, with plans to participate in additional races throughout 2026 and beyond.
Key Takeaways for Readers
- HPV is a global health issue: It affects nearly all sexually active people at some point in their lives and is responsible for 5% of all cancers worldwide.
- Men are at risk, too: HPV can cause cancers of the throat, anus, and penis, as well as genital warts. Vaccination is critical for both boys and girls.
- Vaccination works: The HPV vaccine is highly effective at preventing infections with the most dangerous types of the virus. The WHO recommends vaccination for girls and boys aged 9–14.
- Awareness is growing: Public figures like Eliaz Morineau are helping to break down the stigma around HPV and encourage open conversations about prevention.
- Research is advancing: New treatments, including therapeutic vaccines and antiviral therapies, are in development and could transform HPV prevention and care.
How to Get Involved
If you or someone you know is affected by HPV, there are several ways to take action:
- Get vaccinated: Check with your healthcare provider about HPV vaccination. In many countries, the vaccine is free or subsidized for adolescents and young adults.
- Spread awareness: Share accurate information about HPV with friends, family, and on social media. The more people know, the less stigma there will be.
- Support advocacy groups: Organizations like No Taboo and the HPV Worldwide Alliance work to support patients and promote prevention.
- Talk to your doctor: If you have questions about HPV, vaccination, or screening, don’t hesitate to ask your healthcare provider. Early detection and prevention save lives.
The next major event in Morineau’s campaign is the Solitaire du Figaro, a prestigious solo sailing race set to start in June 2026. His boat, *Figaro 3 “Demain sans HPV”*, will once again serve as a reminder of the importance of HPV prevention—and the power of personal stories to drive change.
Have you or someone you know been affected by HPV? Share your thoughts in the comments below, and help spread awareness by sharing this article with your network.